Parallel plate devices for hemofiltration or hemodialysis are provided. A parallel plate device includes a parallel plate assembly having an aligned stack of stackable plate subunits, each stackable plate subunit having a through channel for blood, where the blood channels are opened up at opposite ends of the parallel plate assembly. The parallel plate assembly is configured to form filtrate/dialysate channels interleaved with the blood channels, adjacent channels being separated by a silicon nanoporous filtration membrane. A blood conduit adaptor is attached to the parallel plate assembly at each of the ends, and is configured to distribute blood to or collect blood from the blood channels. Also provided are systems and methods for using the parallel plate devices.

A membrane obtainable from curing a composition comprising: (i) a curable compound comprising at least two (meth)acrylic groups and a sulphonic acid group and having a molecular weight which satisfies the equation:
MW<(300+300n) wherein: MW is the molecular weight of the said curable compound; and n has a value of 1, 2, 3 or 4 and is the number of sulphonic acid groups present in the said curable compound; and optionally (ii) a curable compound having one ethylenically unsaturated group; wherein the molar fraction of curable compounds comprising at least two (meth)acrylic groups, relative to the total number of moles of curable compounds present in the composition, is at least 0.25.

A membrane obtainable from curing a composition comprising: (i) a curable compound comprising at least two (meth)acrylic groups and a sulphonic acid group and having a molecular weight which satisfies the equation:
MW<(300+300n) wherein: MW is the molecular weight of the said curable compound; and n has a value of 1, 2, 3 or 4 and is the number of sulphonic acid groups present in the said curable compound; and optionally (ii) a curable compound having one ethylenically unsaturated group; wherein the molar fraction of curable compounds comprising at least two (meth)acrylic groups, relative to the total number of moles of curable compounds present in the composition, is at least 0.25.

A hollow fiber membrane module includes: a tubular container accommodating a hollow fiber membrane bundle; headers, and potted parts. The header includes a header protrusion that protrudes in an annular shape toward the tubular container. The tubular container includes double annular protrusions, which are an inner protrusion and an outer protrusion protruding toward the header. The header and the tubular container are welded together by ultrasonic welding, with the header protrusion being inserted between the inner protrusion and the outer protrusion of the tubular container. The header protrusion and the inner protrusion of the tubular container are welded together at least in one or more regions, and the header protrusion and the outer protrusion of the tubular container are welded together at least in one or more regions.

The hollow fiber membrane module according to the present application is provided with a cylindrical container open at one end and the other end, a bundle of hollow fiber membranes packed in the cylindrical container, potting parts embedding and fixing the bundle of hollow fiber membranes at both ends of the cylindrical container, and headers provided at both ends of the cylindrical container and having nozzles that constitute an inlet and outlet for a fluid. In this hollow fiber membrane module, the headers and the cylindrical container are welded in at least two areas including a primary weld and a secondary weld, and the secondary weld is located in a position where welding is initiated after or simultaneously with the beginning of welding of the primary weld.

The present disclosure relates to an apparatus and an apparatus assembly for assessing the suitability of a membrane, such as an osmotic membrane in an osmotic process. Furthermore, the apparatus, and apparatus assembly provide the means to optimise the parameters of an osmotic process, including the ability to gather key data for different membrane based osmotic systems to enable osmotic process and system optimisation.

Devices, systems, and methods herein relate to performing dialysis to manage a chronic condition such as end-stage renal disease. These systems and methods may allow a patient to orally ingest a potable dialysate and excrete the dialysate via the urinary tract. In some variations, a method may include delivering a dialysate via the esophagus of a patient and draining the dialysate into a bladder of the patient. Delivering the dialysate may further comprise delivering the dialysate through the nasopharynx or oropharynx. Delivering the dialysate through the oropharynx may comprise the patient drinking the dialysate.

Devices, systems, and methods herein relate to performing dialysis to manage a chronic condition such as end-stage renal disease. These systems and methods may allow a patient to orally ingest a potable dialysate and excrete the dialysate via the urinary tract. In some variations, a method may include delivering a dialysate via the esophagus of a patient and draining the dialysate into a bladder of the patient. Delivering the dialysate may further comprise delivering the dialysate through the nasopharynx or oropharynx. Delivering the dialysate through the oropharynx may comprise the patient drinking the dialysate.

A treatment system for performing a treatment on a patient may include a treatment fluid preparation device having a pump connected by a fluid channel to a reservoir of a source fluid, the pump conveying the source fluid from the reservoir, through a filter, and combining the source fluid with a concentrate by pumping the source fluid with the concentrate to form a treatment fluid in a batch container. The treatment fluid preparation device may have a controller that controls a heater, the pump, and a memory. The controller starts the heater to warm the treatment fluid in the batch container at a time that is responsive to the treatment time stored in the memory. The controller also detects a pressure property of the filter to determine its integrity and outputs an indication of a failed batch if the pressure property indicates the integrity of the filter is insufficient.

A treatment system for performing a treatment on a patient may include a treatment fluid preparation device having a pump connected by a fluid channel to a reservoir of a source fluid, the pump conveying the source fluid from the reservoir, through a filter, and combining the source fluid with a concentrate by pumping the source fluid with the concentrate to form a treatment fluid in a batch container. The treatment fluid preparation device may have a controller that controls a heater, the pump, and a memory. The controller starts the heater to warm the treatment fluid in the batch container at a time that is responsive to the treatment time stored in the memory. The controller also detects a pressure property of the filter to determine its integrity and outputs an indication of a failed batch if the pressure property indicates the integrity of the filter is insufficient.